Business Context and Reporting Period
Oragenics, Inc. filed this Form 8-K on November 8, 2017, to report a private placement and debt conversion aimed at regaining compliance with NYSE American LLC listing standards. The company had previously been notified of noncompliance with Section 1003(a)(iii) of the NYSE Company Guide, which requires stockholders' equity of at least $6.0 million. The filing details a plan executed by November 10, 2017, to meet this requirement.
Key Financial Metrics
The filing focuses on pro forma stockholders' equity rather than operational revenue or cash flow metrics. Key figures include:
- Private Placement: $3,300,000 raised via Series B Convertible, Non-Voting, Preferred Stock and Warrants.
- Debt Conversion: $3,384,798 of debt owed to Intrexon Corporation exchanged for Series C Non-Convertible, Non-Voting, Preferred Stock.
- Pro Forma Stockholders' Equity: Approximately $6,929,555 as of November 8, 2017.
- Actual Stockholders' Equity (Sept 30, 2017): $1,013,003.
- Accumulated Deficit: Increased from $(99,940,064) to $(100,708,310) on a pro forma basis due to adjustments.
The filing text does not provide clear values for revenue, profit, operating cash flow, or margins.
Material Changes Versus Prior Period
Between September 30, 2017, and November 8, 2017, the company executed a significant capital restructuring:
- Stockholders' equity increased by approximately $5.9 million, moving from $1.01 million to $6.93 million on a pro forma basis.
- The equity increase was driven entirely by the $3.3 million equity raise and the $3.38 million debt-to-equity conversion.
- Common stock shares outstanding remained unchanged at 49,274,219.
- Series B Preferred Stock increased from 0 to 6,600,000 shares issued and outstanding.
- Series C Preferred Stock decreased from 100 to 0 shares as the debt was converted.
Outlook, Risks, and Management Commentary
Management states that the Offering was designed specifically to satisfy the NYSE American LLC stockholders' equity requirement. The company believes it has evidenced compliance with the continued listing standards, subject to review and confirmation by the exchange. The filing does not provide forward-looking guidance on revenue, product development, or future profitability. The primary risk addressed is the potential delisting due to insufficient equity, which the company asserts has been mitigated by this transaction.
Investor Verification Checklist
- Confirm the NYSE American LLC's official acceptance of the company's compliance with the $6.0 million stockholders' equity requirement.
- Verify the terms of the Series B Convertible Preferred Stock and Warrants, including conversion rates and expiration dates.
- Review the full agreement regarding the conversion of the $3,384,798 Intrexon Corporation debt into Series C Preferred Stock.
- Assess the company's ongoing liquidity needs given the continued accumulation of deficit and lack of reported operating revenue in this filing.